Protagonist Therapeutics To Join S&P SmallCap 600, Effective Prior To Opening Of Trading On July 3
Protagonist Therapeutics To Join S&P SmallCap 600, Effective Prior To Opening Of Trading On July 3
protonist therapeutics將於7月3日開盤前加入S&P SmallCap 600指數。
Protagonist Therapeutics to replace Encore Wire in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 3. S&P Europe 350 constituent Prysmian SpA is acquiring Encore Wire in a deal expected to be completed soon pending final conditions.
在週三7月3日開盤前，Protagonist Therapeutics將取代Encore Wire併成爲S&P SmallCap 600指數的成分股。S&P Europe 350的成分股Prysmian SpA正在收購Encore Wire，預計將很快完成交易並等待最終條件。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。